Application of DCE-MRI Based on 4D FreeBreathing in Predicting the Efficacy of Immune and Targeted Therapy in Lung Cancer
Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This study aims to address the challenge of predicting the efficacy of targeted and immunotherapy in lung cancer patients. By utilizing two DCE-MRI images-one before treatment and one after one treatment cycle-along with the patients' clinical and pathological information, we aim to achieve accurate prediction of the therapeutic efficacy of targeted and immunotherapy in lung cancer patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Tumor size greater than 2 cm
• Age between 18 and 75 years
Locations
Other Locations
China
Yunnan Cancer Hospital
RECRUITING
Kunming
Contact Information
Primary
zhihui shi
3332105746@qq.com
15087838660
Backup
Zhenhui Li
lizhenhui@kmmu.edu.cn
13698736132
Time Frame
Start Date: 2024-11-11
Estimated Completion Date: 2026-07-31
Participants
Target number of participants: 195
Treatments
Experimental: Application Value of MRI Imaging in Treatment Decision-Making for Lung Cancer
A Philips 3.0T MRI scanner was used, with a dStream Torso 32-channel coil. DCE-MRI was performed using a free-breathing sequence with a flow velocity of 3.0 m/s. The image quality assessment in this study was performed by two radiologists (one with 3 years of diagnostic experience and the other with 15 years of diagnostic experience), including both subjective and objective evaluations. Then, dynamic information from the 4D FreeBreathing DCE-MRI images taken before treatment and one week after immunotherapy/targeted therapy, along with routine clinical and pathological data, were used to construct predictive models for the efficacy of immunotherapy and targeted therapy. Finally, the MRI model was compared with the CT model, and the performance of both models was evaluated.
Related Therapeutic Areas
Sponsors
Leads: Yunnan Cancer Hospital